Compare CSV & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSV | ANNX |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.5M | 730.4M |
| IPO Year | 1996 | 2020 |
| Metric | CSV | ANNX |
|---|---|---|
| Price | $48.58 | $6.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $59.00 | $16.50 |
| AVG Volume (30 Days) | 89.8K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 54.76 | N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | ★ $417,440,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $3.87 | $16,320.74 |
| P/E Ratio | $14.96 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $38.10 | $1.60 |
| 52 Week High | $49.41 | $7.18 |
| Indicator | CSV | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 61.56 |
| Support Level | $43.62 | $4.79 |
| Resistance Level | $49.29 | $6.50 |
| Average True Range (ATR) | 1.07 | 0.43 |
| MACD | 0.18 | 0.09 |
| Stochastic Oscillator | 87.94 | 85.19 |
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.